Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Board Changes

16 Sep 2009 07:01

RNS Number : 1250Z
TyraTech, Inc.
16 September 2009
Β 

ο»Ώ

For immediate release

16 SeptemberΒ 2009

TYRATECH, INC.

("TyraTech" or "the Company")

Board Changes

TyraTech, Inc. (AIM: TYR), aΒ leading independent novel eco-technology company for human, animal and environmental health, is pleased to announce thatΒ Patrick ReganΒ will join the BoardΒ as aΒ Non-Executive Director andΒ thatΒ DavidΒ PaulΒ SzostakΒ will step down from the Board asΒ aΒ Non-ExecutiveΒ Director.Β MrΒ Szostak joined the Board in April 2008Β to represent XL TechGroupΒ andΒ willΒ nowΒ step down from the Board.Β Both changes take placeΒ with immediate effect.Β 

Mr ReganΒ thirty sevenΒ joins the Board as a representative of theΒ Laurus-ValensΒ Group, the parent Group ofΒ PetroTech Holdings Corporation,Β which has a 45.69% shareholding in TyraTech.Β HeΒ bringsΒ to the Board overΒ sixteenΒ years of financial analysis,Β corporateΒ management,Β investment banking and venture capitalΒ experience gained in theΒ US.Β Mr ReganΒ hasΒ beenΒ a senior managing director for Laurus Capital Management LLC since 2001 andΒ hasΒ also servedΒ the same role at Valens Capital Management LLC since its establishment in 2007.Β 

In addition to hisΒ fund management experience atΒ Laurus-Valens, heΒ hasΒ spent four years as a financial analyst at Geller & Company, a financial services accounting firm,Β primarily providing CFO functions to private companies and financial planning for high net worth individuals. At Geller,Β he was involved in private placement financing, management consulting and general corporate finance functions.Β Between 1999 and 2001,Β PatrickΒ Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm.

Mr Regan has a Bachelor of Science in Business and Economics fromΒ LehighΒ UniversityΒ and an MBA fromΒ FordhamΒ University.Β 

Mr. ReganΒ has no otherΒ previousΒ orΒ current Directorships.Β 

There are no further details required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules.

Commenting on the board changesΒ Geoffrey Vernon, Chairman of TyraTech,Β said:

"I am delighted to welcomeΒ Patrick ReganΒ to the Board as he brings a wealth of experience of matters across a range of different areas important toΒ TyraTech.Β His understanding of the financial dynamics of small cap companiesΒ and hisΒ investment banking and venture capitalΒ experienceΒ will be beneficial to the Group."

"I would like to express my sincere gratitude to DavidΒ for his experience and expertise throughout his timeΒ at TyraTechΒ and wish him well for the future. His contribution has beenΒ highlyΒ valuable."

For further information please contact:

For further information please contact:

TyraTech Inc.

Douglas Armstrong Ph.D., Chief Executive Officer +1 (321) 409 7723

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Charles Walker/Clare Terlouw +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

Mary-Janeί›Β ElliottΒ / Lisa Baderoon +44 (0)20 7466 5000 / Catherine Breen / Stasa Filiplic

www.buchanan.uk.com

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech,Β which already has productsΒ on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech'sΒ Nature's Technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech's plan for the use of its technology is to develop selected proprietary active ingredients which can then be used across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, andΒ for consumer and professional pest control. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium. For more information please visitΒ www.tyratech.comΒ 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAMGGMLMKGGLZZ
Date   Source Headline
8th Nov 20185:25 pmRNSTyratech
2nd Nov 20185:30 pmRNSTyratech
31st Oct 20183:01 pmRNSResult of Special Meeting, Cancellation from AIM
25th Oct 20187:00 amRNSSpecial Meeting and Acquisition Update
18th Oct 20183:00 pmRNSNominee accounts
9th Oct 20182:23 pmRNSPosting of Proxy Statement and Timetable Update
5th Oct 201810:05 amRNSUpdate
28th Sep 20188:50 amRNSInterim Results
28th Sep 20187:00 amRNSConditional Merger Agreement Signed with AMVAC
23rd May 20187:00 amRNSFinal Results
9th May 20187:00 amRNSProgress in 2018 on products and milestones
3rd May 20187:00 amRNSChange of Adviser
24th Jan 20185:44 pmRNSHolding(s) in Company
18th Jan 20187:00 amRNSHolding(s) in Company
15th Jan 20187:00 amRNSResult of Tender Offer
11th Jan 20181:08 pmRNSTR-1
9th Jan 20185:01 pmRNSTR-1
5th Jan 20187:00 amRNSResult of Tender Offer
28th Dec 20177:00 amRNSResult of Special Meeting
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
12th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
24th Aug 20177:00 amRNSCOMPANY UPDATE AND DATE OF INTERIM RESULTS
4th Jul 20172:29 pmRNSJoint Development and License Agreement
29th Jun 20177:00 amRNSResult of AGM
7th Jun 20177:00 amRNSTYR TR-1: Notification of major interest in shares
9th May 20177:00 amRNSResults for the Year Ended 31 December 2016
28th Apr 20173:24 pmRNSFurther re Notice of Final Results
22nd Mar 20178:57 amRNSTR-1: Notification of major interest in shares
9th Feb 20177:00 amRNSPre-close Trading Update
19th Sep 20163:59 pmRNSDirector/PDMR Shareholding
15th Sep 20161:18 pmRNSDirectors' Dealings
13th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
28th Jul 20167:00 amRNSPre Close Trading Update
8th Jun 20163:22 pmRNSResult of AGM and Board Change
22nd Apr 20161:57 pmRNSDirectors' Dealings
15th Apr 201612:03 pmRNSAward of Share Options
15th Apr 201611:57 amRNSDirectors' Dealings
14th Apr 20167:00 amRNSDirectors' Dealings
11th Apr 20167:00 amRNSAppointment of José Barella as Chairman
4th Apr 20167:00 amRNSNotice of Preliminary Results
3rd Feb 201612:31 pmRNSHolding(s) in Company
1st Feb 20161:08 pmRNSDirector's Dealings
1st Feb 20167:00 amRNSPre-close Trading Update
20th Jan 20167:00 amRNSAppointment of Erica H. Boisvert as CFO
13th Jan 20167:00 amRNSNew Product Range Launch & Distribution Agreement
17th Dec 20154:01 pmRNSTR-1: Notification of Major Interest in Shares
4th Dec 201511:00 amRNSTR-1: Notification of major interest in shares
26th Nov 201512:51 pmRNSTR-1: Notification of Major Interest in Shares
16th Nov 20155:01 pmRNSResult of Special Meeting & Director Shareholdings
4th Nov 20157:00 amRNSPlacing and Subscription to raise £3.16m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.